Avanos Medical (AVNS) has drawn investor attention after a period of strong stock performance over the past 3 months, prompting a closer look at how its medical device portfolio and fundamentals align with that move.

Zooming out beyond the recent 3 month surge, Avanos Medical’s share price return of 122.99% year to date and 103.68% total shareholder return over 1 year contrasts with declines over the 3 and 5 year total shareholder return periods.

If Avanos Medical’s move has you thinking about what else is working in healthcare, it could be a good moment to see which other companies are benefiting from AI in medicine through the 41 healthcare AI stocks

With Avanos Medical’s share price up sharply over the past year, set against falling longer term returns and a recent net loss of $74.4 million, the key question is whether there is still value on the table or if the market is already pricing in future growth.

Preferred Price-to-Sales Multiple of 1.6x: Is it justified?

For Avanos Medical, the market is currently paying a P/S of 1.6x, which sits below several comparison points but above an internally estimated fair ratio level.

The P/S ratio compares the company’s market value to its revenue, which can be useful when earnings are negative, as they are here following a net loss of $74.4 million on revenue of $715.9 million. For a medical device company such as Avanos Medical, this multiple gives investors a quick way to relate the $24.93 share price to the scale of its sales rather than profits.

Against the broader US Medical Equipment industry, where the average P/S is 2.7x, Avanos Medical’s 1.6x implies the stock is trading at a lower revenue multiple than many peers. The company also sits below a peer average P/S of 2.3x, which suggests the market is assigning a discount to its revenue base when compared with similar companies.

However, when set against an estimated fair P/S ratio of 1.1x, the current 1.6x level is higher than the regression based fair value benchmark that some investors may treat as a reference point. This creates a tension between the discount implied by peer comparisons and the premium implied by the fair-ratio estimate, which is central to how investors may interpret today’s valuation.

Result: Price-to-sales of 1.6x (ABOUT RIGHT)

However, there are still clear pressure points, including the recent net loss of $74.4 million and a value score of 2, which hints at market reservations.

Next Steps

If the mixed signals around Avanos Medical leave you uncertain, this is the moment to move quickly, review the key risks, and reach your own view by checking the 2 important warning signs.

Looking for more investment ideas beyond Avanos Medical?

If Avanos Medical has sharpened your focus on stock selection, do not stop here. Broaden your watchlist now so you do not miss other compelling opportunities.

• Target potential mispricings by scanning companies trading at a discount to fundamentals through the 42 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with higher, more resilient yields using the 9 dividend fortresses.
• Prioritise resilience by focusing on companies with lower risk profiles via the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.